CoChat
Sign Up
Cited by 124

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B *35:02 as a risk factor

Urban, Thomas Jacob, Nicoletti, Paola, Chalasani, Naga, Serrano, José, Stolz, Andrew, Daly, Ann K., Aithal, Guruprasad P., Dillon, John, Navarro, Victor, Odin, Joseph, Barnhart, Huiman, Ostrov, David, Long, Nanye, Cirulli, Elizabeth Trilby, Watkins, Paul Brent, Fontana, Robert John·2017·Journal of Hepatology
DOI 10.1016/j.jhep.2017.03.010PMC PMC5634615
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.03.010

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
  2. Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 · DOI
  3. Bjornsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
  4. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI
  5. Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI
  6. Spraggs, 2011, HLA-DQA1∗02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197 · DOI
  7. Daly, 2009, HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI
  8. Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  9. DeBoer, 2017, Features of Autoimmune hepatitis in Patients with Drug Induced Liver Injury, Clin Gastro Hep, 15, 103, 10.1016/j.cgh.2016.05.043 · DOI · Paper page
  10. Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI
  11. Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
  12. Benichou, 1993, Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge, J Clin Epidemiol, 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  13. Hicks, 2015, US outpatient Antibiotic Prescribing variation according to geography, Patient population, and Provider Speciality in 2011, Clin Inf Dis, 60, 1308, 10.1093/cid/civ076 · DOI · Paper page
  14. Zheng, 2014, HIBAG–HLA genotype imputation with attribute bagging, Pharmacogenomics J, 14, 192, 10.1038/tpj.2013.18 · DOI
  15. Price, 2006, Principal components analysis corrects for stratification in genome-wide association studies, Nat Genet, 38, 904, 10.1038/ng1847 · DOI · Paper page
  16. Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, 559, 10.1086/519795 · DOI · Paper page
  17. Schwede, 2003, SWISS-MODEL: An automated protein homology-modeling server, Nucleic Acids Res, 31, 3381, 10.1093/nar/gkg520 · DOI
  18. Robinson, 2015, The IPD and IMGT/HLA database: allele variant databases, Nucleic Acids Res, 43, D423, 10.1093/nar/gku1161 · DOI
  19. Morris, 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J Comput Chem, 30, 2785, 10.1002/jcc.21256 · DOI
  20. Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repetoire, PNAS, 109, 9959, 10.1073/pnas.1207934109 · DOI
  21. Illing, 2012, Immune self-reactivity triggered by drug-modified JLA-peptide repetoire, Nature, 486, 554, 10.1038/nature11147 · DOI
  22. Gao, 2001, Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS, N Engl J Med, 344, 1668, 10.1056/NEJM200105313442203 · DOI
  23. He, 2014, Two new susceptibility loci 1q24.2 and 11p11.2 confer risk to severe acne, Nat Commun, 5, 2870, 10.1038/ncomms3870 · DOI
  24. Navarini, 2014, Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris, Nat Commun, 5, 4020, 10.1038/ncomms5020 · DOI
  25. Zhang, 2014, A genome-wide association study of severe teenage acne in European Americans, Hum Genet, 133, 259, 10.1007/s00439-013-1374-4 · DOI · Paper page
  26. Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc Natl Acad Sci U S A, 109, 9959, 10.1073/pnas.1207934109 · DOI
  27. Daly, 2010, Drug-induced liver injury: past, present and future, Pharmacogenomics, 11, 607, 10.2217/pgs.10.24 · DOI
  28. Urban, 2012, Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?, Pharmacogenomics, 13, 735, 10.2217/pgs.12.45 · DOI
  29. Urban, 2014, Genetic basis of drug-induced liver injury: present and future, Semin Liver Dis, 34, 123, 10.1055/s-0034-1375954 · DOI
  30. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI
  31. Monshi, 2012, Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI
  32. Mannargudi, 2009, Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis, Drug Metab Dispo, 37, 1806, 10.1124/dmd.109.027292 · DOI

Cited by

Sorted by citations

Metadata

Authors
Urban, T. J., Nicoletti, P., Chalasani, N., Serrano, J., Stolz, A., Daly, A. K., Aithal, G. P., Dillon, J., Navarro, V., Odin, J., Barnhart, H., Ostrov, D., Long, N., Cirulli, E. T., Watkins, P. B., & Fontana, R. J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2017-07
Volume
67
Issue
1
Pages
137-144
ISSN
0168-8278
DOI
10.1016/j.jhep.2017.03.010
PMC
PMC5634615
Cited by
124
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • NIDDK (2U01-DK065176-06, 2U01-DK065201-06, 2U01-DK065184-06, 2U01-DK065211-06, 5U01DK065193-04, 5U01-DK065238-08, 1U01-DK083023-01, 1U01-DK083027-01, 1U01-DK082992-01, 1U01-DK083020-01)
  • CTSA (UL1 RR025761, UL1TR000083, UL1 RR024134, UL1 RR024986, UL1 RR024982, UL1 RR024150)
  • Intramural Research Program of the NIH
  • National Cancer Institute (DK089464)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review